(IBRX) ImmunityBio, Inc. Complete Analysis Pack
What does ImmunityBio do?
ImmunityBio, Inc. is a Nasdaq-listed commercial-stage biotechnology company centered on ANKTIVA, an interleukin-15 receptor agonist approved with Bacillus Calmette-Guérin, or BCG, for adults with BCG-unresponsive non-muscle-invasive bladder cancer containing carcinoma in situ, with or without papillary tumors. The FDA approval dated April 22, 2024 converted ImmunityBio from a development-stage biotech into a revenue-generating company with commercial, manufacturing, and reimbursement responsibilities.
Which assets define the company?
The research platform is broader than one product, but the economics are not. ImmunityBio combines ANKTIVA with adenovirus-vectored vaccines, natural-killer-cell therapies, immunomodulators, and checkpoint inhibitors across several solid and blood cancers. Almost all commercial revenue currently comes from ANKTIVA, so the pipeline is best viewed as future options financed by one emerging franchise, not as several mature businesses.
Who are the customers and end markets?
The commercial channel includes urologists, oncology practices, hospitals, procedure centers, distributors, payers, and public health systems. Because ANKTIVA is administered into the bladder with BCG, adoption depends on treatment capacity, BCG availability, reimbursement, coding, and physician workflow. The model is more complex than selling an oral drug, but it embeds the product in a specialist pathway where evidence and provider experience can create switching friction.
How does ImmunityBio make money?
ImmunityBio records ANKTIVA sales net of rebates, discounts, returns, co-pay assistance, chargebacks, and other deductions. Product revenue of $44.2 million represented virtually all Q1 2026 revenue. Unlike a diversified biopharmaceutical company, ImmunityBio lacks multiple mature products or royalty streams. Faster adoption could therefore create strong operating leverage, while manufacturing, reimbursement, label, or safety setbacks could affect the entire income statement.
Why is ANKTIVA the economic engine?
| Economic layer | How value is created | Current evidence | Main constraint |
|---|---|---|---|
| Approved U.S. indication | ANKTIVA plus BCG is sold for BCG-unresponsive NMIBC with CIS. | $44.2M product revenue in Q1 2026; 168% year-over-year growth. | Single-product concentration and specialist administration. |
| International commercialization | Partners and subsidiaries distribute approved or authorized labels outside the United States. | European Commission authorization and Saudi commercial availability in 2026. | Country-by-country pricing, reimbursement, and launch execution. |
| Label expansion | Additional NMIBC populations could enlarge the addressable treatment pool without creating a new commercial platform. | Papillary-only supplemental BLA accepted in May 2026. | Regulatory review, trial interpretation, and post-approval uptake. |
| Pipeline combinations | ANKTIVA may be combined with other therapies across solid and hematologic cancers. | Multiple clinical programs, but no additional U.S. approved product as of Q1 2026. | High R&D cost, trial risk, and long development timelines. |
How quickly has product revenue scaled?
The sequence indicates repeat commercial execution rather than a one-time launch shipment. Full-year 2025 product revenue reached $113.0 million on 3,745 units, approximately 700% and 750% above 2024, respectively, according to the company’s FY2025 results release. The test is whether prescriptions, treatment capacity, reimbursement, and international launches can outgrow commercial and development spending.
What does ImmunityBio’s latest quarter show?
The quarter ended March 31, 2026 combined strong revenue growth with unusually volatile reported earnings. Product revenue rose and operating cash use declined year over year, but fair-value changes in warrants and a related-party convertible note produced large noncash charges. Net loss alone therefore obscures the commercial signal, while ignoring those financing liabilities understates the economic burden.
What changed in Q1 2026?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Product revenue | $44.2M | $16.5M | Launch adoption continued; unit sales also rose 168%. |
| Reported gross profit | $44.0M | $16.3M | A 99.5% reported gross margin is temporarily elevated because pre-approval manufacturing costs were previously expensed to R&D. |
| R&D, including related parties | $68.0M | $63.2M | Pipeline investment remained greater than quarterly revenue. |
| SG&A, including related parties | $45.8M | $35.0M | Commercial infrastructure expanded with the revenue base. |
| Operating loss | $69.8M | $82.0M | Operating loss narrowed even as reported net loss widened. |
| Net loss | $632.8M | $129.7M | Fair-value remeasurement, not cash operations, drove most of the increase. |
| Operating cash used | $75.4M | $85.9M | Cash burn improved 12.3% year over year but remained material. |
Why is reported net loss a poor stand-alone KPI?
The Q1 2026 Form 10-Q is best read in layers. Revenue growth measures adoption. Operating loss shows the cost of supporting the franchise and pipeline. Operating cash flow shows financing needs. Fair-value movements explain reported earnings volatility but do not represent equivalent cash outflows in the quarter. For valuation work, all four layers matter, but they should not be collapsed into one net-income multiple.
Which turning points shaped ImmunityBio today?
The history explains ownership concentration, ANKTIVA dependence, manufacturing sensitivity, and commercialization.
How did ANKTIVA move from acquired asset to global franchise?
-
2017The acquisition of Altor BioScience brought the N-803 program that became ANKTIVA. It also created contingent value rights, including a potential $304.0M payment if worldwide ANKTIVA sales exceed $1.0B before the end of 2026.
-
2021NantKwest and private ImmunityBio completed an all-stock merger, and the combined company adopted the ImmunityBio name and IBRX ticker. The merger assembled cell therapy, vaccine, and cytokine assets under founder Patrick Soon-Shiong’s control.
-
2023The FDA issued a complete response letter tied primarily to a pre-license inspection of a third-party contract manufacturer. The later resubmission highlighted how manufacturing readiness can be as decisive as clinical data for a biologic.
-
April–May 2024ANKTIVA received U.S. approval and commercial shipments began. ImmunityBio crossed the strategic boundary from funding trials to building demand, distribution, reimbursement, inventory, and medical-affairs capacity.
-
2025A permanent J-code improved reimbursement mechanics, while product revenue reached $113.0M and unit volume reached 3,745. The company established a measurable commercial trajectory rather than a launch hypothesis.
-
February–April 2026European Commission authorization, distribution infrastructure across Europe, and Saudi commercial availability broadened the addressable geography. Execution now depends on local access and uptake, not approval alone.
-
May 2026The FDA accepted the supplemental BLA for papillary-only BCG-unresponsive NMIBC and set a January 6, 2027 action date. This created a defined near-term catalyst with direct relevance to U.S. market breadth.
What gives ANKTIVA a competitive advantage?
ANKTIVA’s potential moat rests on mechanism, durability, specialist integration, intellectual property, and reuse across indications. The IL-15 receptor agonist is designed to activate natural killer cells and T cells. In bladder cancer, combining it with BCG builds on an established urology workflow rather than requiring an entirely new treatment setting.
Does the biology create differentiation?
| Evidence or resource | Officially reported result | Strategic implication |
|---|---|---|
| Approved CIS population | Updated 71% complete-response rate reported by the company in FY2025 materials. | Supports physician interest in bladder preservation, though cross-trial comparisons require caution. |
| Papillary-only cohort | 58.2% disease-free survival at 12 months and median disease-free survival of 25.3 months. | Provides the clinical basis for a potentially broader NMIBC label. |
| Bladder preservation | 82% cystectomy avoidance at 36 months in the reported papillary cohort. | A meaningful patient-centered outcome where surgery can be life-altering. |
| Intellectual property | Combination patents involving ANKTIVA and checkpoint inhibitors extend beyond 2035. | Could protect selected regimens, subject to patent validity, enforceability, and competing approaches. |
How durable is the advantage?
The moat is incomplete. ANKTIVA relies on BCG supply and repeated intravesical administration, while rivals offer systemic immunotherapy, gene therapy, sustained-release delivery, chemotherapy, or surgery. Reported cost of sales also does not yet show a normalized manufacturing margin because pre-approval inventory costs were expensed earlier. ImmunityBio must convert differentiated evidence into reliable supply, broad access, prescriber confidence, and additional labels before the advantage becomes durable at enterprise scale.
Who are ImmunityBio’s main competitors?
Competition is most direct in bladder-preserving treatment for BCG-unresponsive NMIBC. ImmunityBio’s 2025 Form 10-K identifies Merck and Ferring among relevant competitors. Radical cystectomy remains an established option, while emerging intravesical technologies compete on efficacy, convenience, and treatment burden.
Where is rivalry most intense?
| Competitor or alternative | Strategic position | Pressure on ImmunityBio | ANKTIVA response |
|---|---|---|---|
| Merck’s Keytruda | Systemic checkpoint inhibitor with broad oncology familiarity. | Large commercial organization, established brand, and prescriber experience. | Local intravesical administration and differentiated immune activation. |
| Ferring’s Adstiladrin | Intravesical gene therapy for BCG-unresponsive NMIBC. | Direct competition for bladder-preserving use and treatment-center capacity. | Reported response durability and combination with familiar BCG workflow. |
| TAR-200 and other emerging intravesical platforms | Drug-delivery systems designed for sustained local exposure. | Potential convenience, efficacy, and sequencing advantages if approved. | First-mover commercial experience and expanding real-world physician familiarity. |
| Radical cystectomy and other therapies | Established surgery and alternative intravesical or systemic regimens. | Clinical guidelines and patient-specific risk can favor another path. | Bladder-preservation proposition for suitable patients seeking a non-surgical option. |
How financially strong is ImmunityBio?
ImmunityBio entered Q2 2026 with more liquidity but a liability structure central to valuation. The company is not self-funding: operating cash use was $75.4 million in Q1 2026, while financing activities supplied $223.9 million through equity, warrant exercises, and a revenue-interest transaction. Liquidity improved, but the cost appears through dilution, debt-like claims, revenue sharing, and financial restrictions.
Can liquidity fund the next phase?
| Balance-sheet or cash-flow item | March 31, 2026 | December 31, 2025 | What it means |
|---|---|---|---|
| Cash and marketable securities | $380.9M | $242.8M | A larger liquidity cushion after Q1 financing. |
| Operating cash used | $75.4M in Q1 2026 | $304.9M in FY2025 | Commercial growth has not yet eliminated external funding needs. |
| Approximate free cash flow | -$77.1M in Q1 2026 | Not comparable here | Operating cash flow minus $1.8M of capital and software spending. |
| Total liabilities | $1.516B | $1.001B | Fair-value movements and new financing enlarged the liability base. |
| Stockholders’ deficit | $869.1M | $500.5M | Accumulated losses and liability remeasurement dominate book equity. |
At the Q1 2026 cash-use rate, $380.9 million equals roughly five quarters of operating burn before changes in working capital, clinical spending, debt service, revenue-interest payments, or financing. This is not a formal runway estimate; it shows why revenue growth and cash conversion must improve while access to capital remains open.
What does the liability structure mean?
The revenue-interest agreement provides committed capital but requires payments equal to 5.625% to 12.50% of specified worldwide net sales outside China, subject to an overall cap of 195% of cumulative purchaser funding. In March 2026, the company added $75.0 million and raised total committed capital to $375.0 million through a financing package that also converted $25.0 million of founder-affiliate debt into equity. This reduced immediate cash pressure but gives future revenue to financing counterparties and can complicate a simple enterprise-value bridge.
Who owns ImmunityBio stock?
ImmunityBio has one common share class, but voting power is concentrated. Founder and Executive Chairman Patrick Soon-Shiong beneficially owned 745.5 million shares, or 65.5%, as of April 13, 2026, including securities acquirable within 60 days. The resulting Nasdaq controlled-company status can support long-duration strategy while reducing minority investors’ practical influence.
How much control does the founder have?
| Holder or group | Beneficial shares | Beneficial ownership | Why it matters |
|---|---|---|---|
| Patrick Soon-Shiong | 745.5M | 65.5% | Effective control over elections and major corporate decisions. |
| Nant Capital | 339.5M | 29.9% | Founder-affiliated stake; included within Soon-Shiong’s aggregate ownership. |
| Cambridge Equities | 261.7M | 25.0% | Founder affiliate with a director-designation right while ownership remains at least 20%. |
| Directors and executive officers as a group | 756.8M | 66.1% | Management and board insiders collectively dominate voting outcomes. |
The stakes overlap and should not be added together. The 2026 proxy statement separately noted that founder-affiliated shares represented about 62.5% of shares entitled to vote at the annual meeting; the 65.5% beneficial-ownership figure also includes shares acquirable within 60 days.
What oversight exists despite concentrated control?
Six of nine directors were independent under Nasdaq standards, and the board maintained Audit, Compensation, Governance, and Related Party Transaction committees. The board met nine times in 2025, with each director attending at least 75% of applicable meetings. These structures matter because the company regularly transacts with founder-affiliated entities, carries a related-party convertible note, and depends on founder-controlled voting power. Independent process is therefore not cosmetic; it is central to evaluating financing terms, conflicts, executive incentives, and capital allocation.
What opportunities could change ImmunityBio’s growth path?
The largest opportunity is to turn ANKTIVA from a focused launch into a broader immunotherapy franchise by deepening U.S. adoption, adding adjacent bladder-cancer populations, and scaling international access. These routes reuse the manufacturing, medical, and commercial platform, creating potential operating leverage.
Which growth milestones matter most?
The papillary-only filing is the clearest near-term expansion because it targets the same disease setting and commercial channel. The company said approximately 85% of the roughly 64,000 annual U.S. NMIBC diagnoses present with papillary disease; the accepted supplemental BLA therefore addresses a materially broader population than CIS alone. Internationally, the European Commission authorization covers the European Union plus Iceland, Norway, and Liechtenstein, while a official distribution partnership provides an 85-person field force across 30 countries. Approval expands possibility; reimbursement and utilization determine economics.
What risks could weaken ImmunityBio’s outlook?
The risk profile is concentrated. ANKTIVA must grow, manufacturing must remain compliant, reimbursement must work, financing must remain available, and trials must produce regulatory-grade evidence. Slower adoption raises cash burn and dilution pressure; manufacturing problems can disrupt revenue and clinical programs.
Which risks are most material, and what should be monitored?
| Risk | Current factual anchor | Financial line affected | Monitor next |
|---|---|---|---|
| Product concentration | One U.S.-approved commercial product as of Q1 2026. | Revenue, inventory, gross profit, and enterprise value. | Sequential units, gross-to-net deductions, and treatment-center growth. |
| Financing and dilution | 1.047B shares outstanding at March 31, 2026 versus 1.012B at year-end 2025. | Per-share value, interest expense, and future revenue sharing. | Cash burn, equity issuance, warrant exercises, and RIPA draws. |
| Manufacturing and BCG dependence | A 2023 complete response letter was tied primarily to a third-party manufacturing inspection. | Supply, cost of sales, trial timelines, and sales continuity. | Inventory availability, inspection outcomes, and normalized gross margin. |
| Regulatory communication | A March 2026 FDA warning letter challenged claims implying uses beyond the U.S. label. | Compliance costs, launch execution, reputation, and promotional flexibility. | Corrective actions and alignment of promotional materials with approved indications. |
| Clinical and label-expansion risk | Papillary-only review remains pending with a January 6, 2027 action date. | Probability-adjusted revenue and R&D value. | FDA review, trial durability, safety, and filing timelines. |
| Founder control and related parties | Patrick Soon-Shiong beneficially owned 65.5% as of April 13, 2026. | Governance discount, transaction terms, and strategic flexibility. | Related-party approvals, note conversions, and board oversight. |
The FDA warning letter dated March 13, 2026 is a concrete reminder that scientific ambition and promotional language must remain separate from approved labeling. The agency stated that certain communications implied unapproved uses, including broad cancer treatment, lung cancer after checkpoint failure, and cancer prevention. The issue does not erase the approved bladder-cancer franchise, but it increases the importance of compliance controls while the company pursues multiple indications.
What is the key takeaway for ImmunityBio valuation?
ImmunityBio is no longer only a clinical probability. ANKTIVA generated $113.0 million of FY2025 product revenue and $44.2 million in Q1 2026. Label expansion, international authorizations, and the IL-15 platform add upside; operating losses, high cash use, liabilities above $1.5 billion, founder control, and product concentration add risk.
Which DCF drivers matter most?
What should a student, researcher, or investor conclude?
ImmunityBio should be modeled as both a commercial franchise and a probability-adjusted pipeline. The approved business requires product-level assumptions for adoption, realized price, normalized margin, operating expense, and cash conversion. Unapproved indications require separate probabilities. Financing liabilities, dilution, and founder control must then be reflected in enterprise-to-equity and per-share analysis.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.